FDA label

What is Jornay PM used for?

Jornay PM contains methylphenidate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.

Source: DailyMed SPL label file dated 2026-10-23. Publisher page

The FDA label says: “JORNAY PM is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.”

Run it in Rivvi

Which 2027 plans near you dropped or restricted Jornay PM?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Jornay PM, capsule

Indications and Usage, quoted from the label by Ironshore Pharmaceuticals Inc. (NDA209311). Cross-references to other label sections are left out.

JORNAY PM is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Limitations of Use

The use of Jornay PM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Source: DailyMed label, set id d95dede0-b1ff-4489-8f91-3bbe122852bf, version 16, effective October 3, 2025. NDC 71376-201, one of 5 listings for this product.

Questions

What is Jornay PM used for?

The FDA label says: “JORNAY PM is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.”

What drug class is Jornay PM?

FDA lists methylphenidate in the Central Nervous System Stimulant established pharmacologic class.

Does this page cover off-label uses or dosing?

No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.

More on Jornay PM

Try it on your own data today.

Free to start. Most teams are using it the same day.